Evidence map›Paper›PMID 40799893›Full record

ArticleCureus2025

Lack of Effect of Omecamtiv Mecarbil on Smooth Muscle Myosin Phosphatase Target Subunit-1 (MYPT1) Phosphorylation and Hemodynamics in Rats.

Marina Takata, Mika Nishikawa, Hisaki Hayashi, Aya Yamamura, Keita Saku, Toru Kawada, Motohiko Sato, Shinji Kawahito, Hiroyuki Kinoshita

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marina TakataDepartment of Dental Anesthesiology, Tokushima University Hospital, Tokushima, JPN.
Mika NishikawaDepartment of Dental Anesthesiology, Tokushima University Hospital, Tokushima, JPN.
Hisaki HayashiDepartment of Physiology, Aichi Medical University, Nagakute, JPN.
Aya YamamuraDepartment of Physiology, Aichi Medical University, Nagakute, JPN.
Keita SakuDepartment of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, JPN.
Toru KawadaDepartment of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, JPN.
Motohiko SatoDepartment of Physiology, Aichi Medical University, Nagakute, JPN.
Shinji KawahitoDepartment of Dental Anesthesiology, Tokushima University Hospital, Tokushima, JPN.
Hiroyuki KinoshitaDepartment of Anesthesiology, Seirei Mikatahara General Hospital, Hamamatsu, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background It remains unclear whether omecamtiv mecarbil, a cardiac myosin direct activator, enhances vascular smooth muscle myosin function at clinical and supra-clinical doses. Aims The current study evaluated the effect of omecamtiv mecarbil, a cardiac myosin activator, on vascular smooth muscle contraction mediated by myosin phosphatase target subunit-1 (MYPT1) phosphorylation in rats. Methods Endothelium-denuded rat aortic rings underwent isometric force recordings (n = 7-9) and western immunoblotting (n = 5) to assess vascular smooth muscle MYPT1 phosphorylation. Aortic rings were incubated with phenylephrine, omecamtiv mecarbil (10

Indexed as

blood pressureblood vesselcontractionmyosinomecamtiv mecarbilvascular smooth muscle

Identifiers

PMID40799893
PMCPMC12342963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.